Valuation: argenx SE

Market Cap 56.07B 50.22B 46.33B 41.93B 78.4B 5,339B 79.67B 553B 221B 2,794B 210B 206B 8,850B P/E 2026 *
29.7x
P/E 2027 * 25.9x
Enterprise Value 52.25B 46.8B 43.17B 39.07B 73.06B 4,975B 74.24B 515B 205B 2,604B 196B 192B 8,247B EV / Sales 2026 *
8.2x
EV / Sales 2027 * 6.45x
Free-Float
99.99%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day+0.98%
1 week+2.26%
Current month-5.01%
1 month-4.76%
3 months+4.20%
6 months+20.85%
Current year+12.22%
1 week 771.2
Extreme 771.2
815.6
1 month 682
Extreme 682
862.4
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Date Insider Type Main position Quantity % Market Cap. Importance
23/11/25 Sell

Chief Executive Officer

2,000 0.0032%
23/11/25 Sell

Director

4,680 0.0076%
23/11/25 Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%+2.26%+12.91%+82.98% 55.53B
+0.34%-3.03%+37.45%+61.06% 64.14B
+1.75%+2.76%+12.38%+103.69% 53.03B
-1.43%-1.17%+26.27%+55.26% 45.99B
-0.48%-2.80%+18.01%+99.11% 42.45B
+0.82%+1.37%+227.94%+936.89% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+44.58%+102.84%+88.74% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
+1.30%-0.60%-13.76%-4.42% 22.1B
Average -0.20%+3.08%+45.75%+146.29% 41.46B
Weighted average by Cap. -0.04%+2.77%+46.08%+151.82%

Financials

2026 *2027 *
Net sales 6.37B 5.71B 5.27B 4.76B 8.91B 607B 9.05B 62.82B 25.06B 318B 23.91B 23.4B 1,006B 7.77B 6.96B 6.42B 5.81B 10.87B 740B 11.05B 76.65B 30.58B 387B 29.18B 28.56B 1,227B
Net income 1.83B 1.64B 1.51B 1.37B 2.55B 174B 2.59B 18B 7.18B 90.99B 6.85B 6.71B 288B 2.11B 1.89B 1.75B 1.58B 2.95B 201B 3B 20.83B 8.31B 105B 7.93B 7.76B 333B
Net Debt -3.82B -3.42B -3.16B -2.86B -5.34B -364B -5.43B -37.68B -15.03B -190B -14.34B -14.04B -603B -5.91B -5.29B -4.88B -4.42B -8.26B -563B -8.39B -58.24B -23.24B -294B -22.17B -21.7B -933B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
29/10/26 €804.40 +0.98% 62,464
28/10/26 €796.60 +1.76% 67,787
27/10/26 €782.80 +0.33% 60,326
26/10/26 €780.20 -0.26% 65,204
23/10/26 €782.20 -0.15% 105,922
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
887.87USD
Average target price
1,121.73USD
Spread / Average Target
+26.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - argenx SE
  1. Stock Market
  2. Stocks
  3. ARGX Stock